Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

TEVA - Teva Pharmaceutical Industries... | Finranks

Home

/

TEVA

T

Teva Pharmaceutical Industries Limited (TEVA)

NYQ – Real vaqt narxi. Valyuta: USD

36.60

+0.12 (0.32%)

Bozor ochiq: Aug 12, 2026, 1:13 PM EDT

36.51

+0.03 (0.08%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?

SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?

Investors with an interest in Medical - Generic Drugs stocks have likely encountered both Supernus Pharmaceuticals (SUPN) and Teva Pharmaceutical Industries Ltd. (TEVA). But which of these two stocks is more attractive to value investors?

Teva seeks to keep Israel ties from jury, cites Gaza war

Teva seeks to keep Israel ties from jury, cites Gaza war

Teva Pharmaceuticals has asked a U.S. judge to prevent insurer Humana from telling jurors it is an Israeli company at a major drug ‌price-fixing trial, arguing that strong public views over the Gaza war could prejudice proceedings and affect its ability to receive a fair hearing.

Teva Pharmaceuticals: Continuing To Execute On Its 'Pivot To Growth' Plan

Teva Pharmaceuticals: Continuing To Execute On Its 'Pivot To Growth' Plan

Teva Pharmaceutical Industries Limited is executing a successful turnaround, driven by its "Pivot to Growth" strategy and strong innovative medicines performance. Management raised 2026 guidance for Austedo, Ajovy, and Uzedy, targeting $3.7B specialty revenue (17% y/y growth) and a robust pipeline through 2030. Generics and biosimilars remain stable, funding R&D for innovation, while margin improvements and debt reduction enhance the risk/reward profile.

Teva's Re-Rating Still Has Room To Run

Teva's Re-Rating Still Has Room To Run

Teva Pharmaceutical is undergoing a transformation, shifting its revenue mix toward specialty and innovative drugs, now over $1 billion per quarter. TEVA targets $3.7 billion in specialty/innovative sales for 2026 and aims for operating margins near 30% by 2027, driven by product mix and cost savings. Leverage has dropped below 3x EBITDA, with a goal of 2x by 2027, supported by $2–$2.4 billion free cash flow guidance for 2026.

Why Teva Pharmaceutical Stock Surged This Week

Why Teva Pharmaceutical Stock Surged This Week

Teva posted its Q2 results this week, reporting an earnings miss even though sales beat expectations. The company's forward guidance didn't deliver big surprises, but it looked solid enough.

Videolar

No Data

There is no data to display